Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc..
The board of directors of Harpoon has unanimously approved the transaction. The board of directors of Merck Sharp & Dohme has approved the transaction. The transaction is subject to certain conditions, including approval of the merger by Harpoon?s stockholders, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and other customary conditions. Harpoon Therapeutics shareholders will hold a meeting on March 8, 2024 to approve the transaction. The HSR Waiting Period expired at 11:59 p.m., Eastern Time, on February 21, 2024. As of March 8, 2024, Harpoon's shareholder's approval received. The transaction is expected to close in the first half of 2024.
Catherine J. Dargan, Andrew M. Fischer and Michael J. Riella of Covington & Burling LLP acted as its legal advisor and Evercore Group L.L.C. acted as financial advisor to Merck. Stuart M. Cable, Lisa R. Haddad, Jean A. Lee, Amanda Gill, Maggie L. Wong, Marianne C. Sarrazin, Alex Apostolopoulos, Arman Oruc, Jacob R. Osborn, Christopher J. Denn, Julie Tibbets, Nathan J. Brodeur, Jacqueline Klosek, Lore Leitner, Robert M. Hale, Alexandra S. Denniston, Andrew C. Sucoff, Matt Wetzel, Deborah S. Birnbach, Alicia Tschirhart, Simone Waterbury, Brian H. Mukherjee and Christina Ademola of Goodwin Procter LLP acted as legal advisor and Centerview Partners LLC acted as financial advisor and fairness opinion provider to Harpoon and will receive a fee of approximately $22.5 million, $1 million of which was payable upon the rendering of Centerview?s opinion. Mackenzie Partners, Inc. acted as information agent to Harpoon Therapeutics and will receive a fee of $18,500 for its service. Computershare Trust Company, N.A. acted as transfer agent to Harpoon. Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor to Harpoon Therapeutics, Inc.
Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc. (NasdaqCM:HARP) on March 11, 2024.